Education
About Us
Working with TipRanks
Follow Us
Tiziana Life Sciences (US) (TLSA)
NASDAQ:TLSA
TLSA Stock Chart & Stats
$1.79
$0.02(2.50%)
At close: 4:00 PM EST
$1.79
$0.02(2.50%)
Day’s Range― - ―
52-Week Range$0.63 - $2.60
Previous CloseN/A
Volume79.40K
Average Volume (3M)345.27K
Market Cap
$173.52M
Enterprise ValueN/A
Total Cash (Recent Filing)$7.25M
Total Debt (Recent Filing)$107.00K
Price to Earnings (P/E)―
Beta-1.10
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding118,851,950
10 Day Avg. Volume569,921
30 Day Avg. Volume345,274
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)9.43
Price to Sales (P/S)0.00
P/FCF Ratio-30.08
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)N/A
Tiziana Life Sciences News
TLSA FAQ
What was Tiziana Life Sciences (US)’s price range in the past 12 months?
Tiziana Life Sciences (US) lowest stock price was $0.63 and its highest was $2.60 in the past 12 months.
What is Tiziana Life Sciences (US)’s market cap?
Tiziana Life Sciences (US)’s market cap is $173.52M.
When is Tiziana Life Sciences (US)’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tiziana Life Sciences (US)’s earnings last quarter?
Currently, no data Available
Is Tiziana Life Sciences (US) overvalued?
According to Wall Street analysts Tiziana Life Sciences (US)’s price is currently Overvalued.
Does Tiziana Life Sciences (US) pay dividends?
Tiziana Life Sciences (US) does not currently pay dividends.
What is Tiziana Life Sciences (US)’s EPS estimate?
Tiziana Life Sciences (US)’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tiziana Life Sciences (US) have?
Tiziana Life Sciences (US) has 118,851,950 shares outstanding.
What happened to Tiziana Life Sciences (US)’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tiziana Life Sciences (US)?
Currently, no hedge funds are holding shares in TLSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tiziana Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
TLSA Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $401.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
114.39%
12-Months-Change
Fundamentals
Return on Equity
-232.31%
Trailing 12-Months
Asset Growth
51.38%
Trailing 12-Months
Company Description
Tiziana Life Sciences (US)
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
Technical Analysis
Ownership Overview
39.00% Insiders
0.07% Mutual Funds
2.74% Other Institutional Investors
58.19% Public Companies and
Individual Investors